Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines.

doi:10.1007/s11060-024-04672-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines.

Journal of neuro-oncology - 1 Jun 2024

Kocher Daniela, Cao Lei, Guiho Romain, Langhammer Melanie, Lai Yun-Lu, Becker Pauline, Hamdi Hiba, Friedel Dennis, Selt Florian, Vonhören David, Zaman Julia, Valinciute Gintvile, Herter Sonja, Picard Daniel, Rettenmeier Johanna, Maass Kendra K, Pajtler Kristian W, Remke Marc, von Deimling Andreas, Pusch Stefan, Pfister Stefan M, Oehme Ina, Jones David T W, Halbach Sebastian, Brummer Tilman, Martinez-Barbera Juan Pedro, Witt Olaf, Milde Till, Sigaud Romain

Abstract excerpt

INTRODUCTION: Patients with pediatric low-grade gliomas (pLGGs), the most common primary brain tumors in children, can often benefit from MAPK inhibitor (MAPKi) treatment. However, rapid tumor regrowth, also referred to as rebound growth, may occur once treatment is stopped, constituting a significant clinical challenge. METHODS: Four patient-derived pediatric glioma models were investigated to model rebound...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytokines

Share to Glioma

Share to MAP Kinase Signaling System

Share to Microglia

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 38630384
DOI: 10.1007/s11060-024-04672-9
PMCID: PMC11147834

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines.PMID 38630384Read ↗

Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.Semantic proximity Read ↗

MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomasSemantic proximity Read ↗

An <i>ex vivo</i> functional biomarker of treatment response in pediatric low-grade gliomaSemantic proximity Read ↗

BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma.Semantic proximity Read ↗

Pediatric low-grade gliomas: molecular characterization of patient-derived cellular models.Semantic proximity Read ↗

The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models.Semantic proximity Read ↗

Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma modelsSemantic proximity Read ↗

BRAF and MEK Targeted Therapies in Pediatric Central Nervous System TumorsSemantic proximity Read ↗

Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas.Semantic proximity Read ↗

A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells.Semantic proximity Read ↗

MAPK/ERK signaling in gliomas modulates interferon responses, T cell recruitment, microglia phenotype, and immune checkpoint blockade efficacySemantic proximity Read ↗

Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.